Tempus and Recursion Extend Data Partnership Through November 2029
Tempus AI, Inc. announced on September 21, 2026 that it has extended its data license agreement with Recursion Pharmaceuticals, Inc. through November 2029, and that the two companies have entered into a separate agreement under which Tempus will license Recursion's RNA foundation model. In connection with the extension, the parties agreed to amend the Annual License Fees payable under their original Master Agreement, replacing discretionary license fees potentially totaling US$84 million over…